Scott Cameron: Metformin, Aspirin, and Sex-Specific Effects in Abdominal Aortic Aneurysm Growth
Scott Cameron, Vascular cardiologist at Cleveland Clinic, Section Head of Vascular Medicine, shared a post on LinkedIn about a recent article he and his colleagues co-authored, adding:
“Proud to share the third first‑author manuscript accepted from our National Heart, Lung, and Blood Institute funded Cleveland Clinic Lerner College of Medicine Prism Ph.D. student and former vascular medicine fellow, Fahad Alkhalfan.
Examining a large cohort of patients from the Cleveland Clinic Heart, Vascular, and Thoracic Institute, Dr. Alkhalfan shows that rapid abdominal aortic aneurysm (AAA) growth is mitigated by metformin and aspirin use.
Most strikingly, the data reveal a sex‑specific effect: ACE inhibitors and ARBs were associated with slower AAA growth ONLY in women.
Strict BP control is a Class I recommendation in the 2022 AHA/ACC guidelines for treating AAA medically, but there is less guidance on the class of medications to use
Another important piece of the AAA biology puzzle—and a clear reminder of why we must enroll more women in clinical trials and invest in mechanistic research focused on women’s cardiovascular health. Outstanding work and an important step toward more precise and equitable vascular care.”
Title: Sex-based differences in cardiovascular risk management and abdominal aortic aneurysm growth: Insights from a contemporary cohort study
Authors: Fahad Alkhalfan, Essa Hariri, Anu Aggarwal, Pulkit Chaudhury, Natalia Fendrikova Mahlay, Robert Burton, A. Phillip Owens III, Scott J. Cameron
Read Full Article on Atherosclerosis
Stay updated with Hemostasis Today.
-
Apr 23, 2026, 18:19Chokri Ben Lamine: Choosing the Right LMWH in Cancer Patients
-
Apr 23, 2026, 17:57Shalini R: Not All Blood Thinners Are the Same
-
Apr 23, 2026, 17:33Abdulaziz (Omar) Badran: Navigating the Clinical Complexity of Combined Red Cell Disorders
-
Apr 23, 2026, 17:19Kate Thomas: One Hour, One Donation, One Life Saved
-
Apr 23, 2026, 17:19Ameneh Eshghinejad: The First 72 Hours After SAH Are Critical for Balancing the Risks of Rebleeding and Thromboembolism
-
Apr 23, 2026, 17:18Katarina Ziakova: The WFH Shared Decision – Making Tool Is Driving Critical Conversations in Haemophilia Care
-
Apr 23, 2026, 17:14Paulus Kirchhof: Can We Improve Prevention of Cardiovascular Diseases?
-
Apr 23, 2026, 17:08Wolfgang Miesbach: 5‑Year Gene Therapy Data from WFH Congress 2026
-
Apr 23, 2026, 17:05Veronica Sanchez: The 2026 Guideline on the Management of Dyslipidemia